Physician

Mark Armando Prendes, M.D.

According to 2025 Medicare claims, Mark Prendes, M.D. (NPI: 1073874954) practices ophthalmology in the Sandusky, OH market, with the plurality of this provider's patient population coming from Erie, OH. This provider's primary affiliated billing organization is OPHTHALMOLOGY & OCULOPLASTIC SURGERY INC (NPI: 1073713400; TIN: 341770577) and primary practice location at 44870-5311. Prendes is affiliated with the Mercy Health Select, LLC (ACO ID: A1215), participating under the MSSP model.

Prendes' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 403 traditional Medicare patients, billed 943 HCPCS/CPT codes, and received $166,215 in Medicare payments. The top billing code was 15823 (Removal of excessive skin and fat of upper eyelid). Part D data shows 341 prescription claims across 225 beneficiaries totaling $3,467 in drug costs, led by Erythromycin (Erythromycin Base). Open Payments data shows 12 records totaling $351. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $9,135 to $166,215. In contrast, Part D prescription costs have fallen sharply in recent years, from $13,896 to $3,467. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$83K$166K2018 Medicare payment: $9,135 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $58,955 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $58,087 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $68,184 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $68,757 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $80,509 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $166,215 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
20184078$9,135
2019218997$58,955
20201991,656$58,087
20212321,404$68,184
20222461,916$68,757
20232282,991$80,509
2024403943$166,215

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$426K$852K2015 Drug cost: $13,896 (USD; Tot_Drug_Cst)2016 Drug cost: $7,977 (USD; Tot_Drug_Cst)2017 Drug cost: $2,553 (USD; Tot_Drug_Cst)2018 Drug cost: $429 (USD; Tot_Drug_Cst)2019 Drug cost: $2,692 (USD; Tot_Drug_Cst)2020 Drug cost: $378,745 (USD; Tot_Drug_Cst)2021 Drug cost: $851,746 (USD; Tot_Drug_Cst)2022 Drug cost: $2,718 (USD; Tot_Drug_Cst)2023 Drug cost: $1,824 (USD; Tot_Drug_Cst)2024 Drug cost: $3,467 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201590274$13,896
2016104299$7,977
201785156$2,553
20181922$429
20195083$2,692
20204275$378,745
20214075$851,746
20224573$2,718
20235389$1,824
2024225341$3,467

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
15823Removal of excessive skin and fat of upper eyelid8787$609
99204New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more198198$115
99203New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more5656$78
92083Exam of visual field with extended testing5758$45
92081Exam of visual field with limited testing7274$23

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
ErythromycinErythromycin Base1672,339$1,563
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha811,390$813
ValacyclovirValacyclovir Hcl1498$138
CephalexinCephalexin21179$80

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.12$351Amgen Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Mark Armando Prendes, M.D.?

Tedicare shows public-source Medicare data for Mark Armando Prendes, M.D. (NPI 1073874954), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Armando Prendes, M.D. have ACO affiliation data?

Mark Armando Prendes, M.D. is shown with ACO affiliation data for Mercy Health Select, LLC (MSSP, ACO ID A1215).

What billing organization is linked to Mark Armando Prendes, M.D.?

Mark Armando Prendes, M.D. is linked to OPHTHALMOLOGY & OCULOPLASTIC SURGERY INC (billing NPI 1073713400) in the available physician profile data.

Does Mark Armando Prendes, M.D. have Open Payments data?

Mark Armando Prendes, M.D. has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.